GeneHealth - Your precision medicine

Autosomal Dominant Familial Periodic Fever

Disease Details

Family Health Simplified

Buy Membership

Description: Autosomal dominant familial periodic fever is a hereditary condition characterized by recurrent episodes of fever and inflammation affecting various systems in the body.
Type: Autosomal Dominant Familial Periodic Fever is transmitted via autosomal dominant inheritance. This means that only one copy of the mutated gene, inherited from either parent, is sufficient to cause the disorder.
Signs And Symptoms: Autosomal Dominant Familial Periodic Fever (ADFPR) is characterized by recurrent episodes of fever accompanied by a range of signs and symptoms. These may include:

- Fever episodes lasting from a few days to a week.
- Abdominal pain.
- Muscle pain (myalgia).
- Joint pain (arthralgia).
- Skin rash.
- Swelling of lymph nodes (lymphadenopathy).
- Inflammation of the lining of the abdomen (peritonitis) when severe.
- Sometimes, inflammation of the lining around the heart (pericarditis) or lungs (pleuritis).

These episodes often occur without a clear trigger and can significantly impact the quality of life.
Prognosis: Autosomal Dominant Familial Periodic Fever, also known as Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), has a variable prognosis. The severity and frequency of fever episodes can differ significantly among individuals. Some may experience mild symptoms manageable with treatment, while others may have more severe and frequent episodes. Regular monitoring by a healthcare professional is crucial for managing symptoms and preventing complications. Early and appropriate intervention can improve the quality of life for affected individuals.
Onset: Autosomal dominant familial periodic fever typically has an onset in early childhood, although the exact age can vary among individuals.
Prevalence: The prevalence of autosomal dominant familial periodic fever, also known as Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), is not precisely known but is considered very rare. Estimates suggest it affects approximately 1 in 1,000,000 people.
Epidemiology: Autosomal Dominant Familial Periodic Fever is a rare genetic disorder characterized by recurrent episodes of fever, rash, and joint pain. Epidemiological data for this specific condition is limited due to its rarity, making precise incidence and prevalence rates challenging to determine. Generally, such conditions are inherited in an autosomal dominant pattern, meaning a single copy of the altered gene in each cell is sufficient to cause the disorder.
Intractability: Autosomal Dominant Familial Periodic Fever, also known as Familial Mediterranean Fever (FMF), is typically manageable but may not be entirely curable. The condition is characterized by recurrent episodes of fever and inflammation. Treatment usually involves medications like colchicine to reduce the frequency and severity of attacks and prevent complications. With appropriate management, many individuals can lead relatively normal lives, but the disease requires ongoing treatment to control symptoms and prevent long-term damage.
Disease Severity: Autosomal Dominant Familial Periodic Fever (ADFPR) typically presents with recurrent episodes of fever, rash, arthritis, and abdominal pain. The severity can vary widely among individuals, ranging from mild to debilitating. Some individuals may experience symptoms that significantly impact their quality of life, while others might have more manageable conditions. There is no known association between ADFPR and the chemical element nan (presumably, you might mean 'NaN' or 'nanotechnology'), as ADFPR is a genetic condition. If you need information on different aspects of the disease, such as treatment or genetic basis, please specify.
Healthcare Professionals: Disease Ontology ID - DOID:0090018
Pathophysiology: Autosomal dominant familial periodic fever, also known as Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), is a rare inherited condition characterized by recurrent episodes of fever and inflammation. The pathophysiology of TRAPS involves mutations in the TNFRSF1A gene, which encodes the tumor necrosis factor receptor 1 (TNFR1). These mutations disrupt the function of TNFR1, leading to prolonged activation of inflammatory pathways.

Specifically, the abnormal TNFR1 can cause continuous activation of NF-κB signaling and increased production of pro-inflammatory cytokines such as IL-1β and TNF-α. This constant inflammation results in the periodic fever episodes and other symptoms like abdominal pain, muscle pain, and skin rashes. The phenotypic expression can vary, but these inflammatory attacks significantly affect the patient's quality of life. Treatment typically involves anti-inflammatory and immune-modulating therapies, including corticosteroids and biologics targeting specific cytokines.
Carrier Status: In the context of autosomal dominant familial periodic fever, carrier status is generally not applicable. This is because, in autosomal dominant conditions, having just one copy of the mutated gene can cause the disease. Therefore, individuals with the mutation typically exhibit symptoms, rather than being asymptomatic carriers.
Mechanism: Autosomal dominant familial periodic fever is typically associated with mutations in the TNFRSF1A gene, which encodes the tumor necrosis factor receptor 1 (TNFR1). The underlying mechanism involves dysregulation of the inflammatory response due to these genetic alterations.

**Molecular Mechanisms:**
1. **TNFR1 Dysfunction:** Mutations in TNFRSF1A lead to either misfolding of the TNFR1 protein or altered receptor signaling. This can cause improper activation or suppression of downstream inflammatory pathways.

2. **Inflammasome Activation:** Altered TNFR1 function can result in enhanced activation of the inflammasome complex, leading to increased production and release of pro-inflammatory cytokines such as IL-1β.

3. **Proteasome Impairment:** Misfolded TNFR1 proteins may be inadequately degraded by the proteasome system, contributing to cellular stress and further promoting inflammatory responses.

4. **NF-κB Pathway:** Changes in TNFR1 signaling may affect the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, a critical regulator of immune and inflammatory responses.

The combination of these molecular dysfunctions culminates in recurrent episodes of fever and systemic inflammation characteristic of this condition.
Treatment: Treatment for autosomal dominant familial periodic fever primarily focuses on managing and alleviating symptoms. Common approaches include:

1. **Nonsteroidal Anti-inflammatory Drugs (NSAIDs)**: For reducing fever and inflammation.
2. **Corticosteroids**: To control severe flare-ups.
3. **Colchicine**: Often used to prevent episodes.
4. **Biologics**: Such as interleukin-1 inhibitors (e.g., anakinra, canakinumab) for more severe cases.
5. **Regular Monitoring and Supportive Care**: To manage symptoms and maintain general health.

Each treatment plan is tailored to the individual based on the severity and frequency of their symptoms. Regular follow-up with a healthcare provider specializing in genetic or inflammatory disorders is important for optimal management.
Compassionate Use Treatment: Autosomal Dominant Familial Periodic Fever (ADFPF), also known as Familial Mediterranean Fever (FMF) type 2, tends to have limited treatment options. Here are some current approaches outside standard protocols:

1. **Compassionate Use Treatments:**
- **Investigational Drugs:** In cases where standard treatments fail, physicians might seek to use investigational drugs through compassionate use programs. These programs allow access to drugs that are still in the trial phase for patients with serious diseases who lack other treatment options.

2. **Off-label Treatments:**
- **Interleukin-1 (IL-1) Inhibitors:** Medications like anakinra and canakinumab, which are IL-1 inhibitors, can be used off-label to help manage inflammation in ADFPF.
- **TNF-alpha Inhibitors:** Drugs like etanercept, infliximab, and adalimumab may be considered off-label for controlling inflammatory symptoms.

3. **Experimental Treatments:**
- **Gene Therapy:** Though still in experimental stages, gene therapy could potentially correct the underlying genetic mutations responsible for ADFPF.
- **Small Molecule Inhibitors:** Research is ongoing into small molecules that might target specific pathways involved in the disease process.

It is important for patients to discuss these options with their healthcare provider to weigh potential benefits and risks.
Lifestyle Recommendations: Autosomal dominant familial periodic fever is a genetic condition characterized by recurrent episodes of fever and inflammation. Lifestyle recommendations to manage the condition typically include:

1. **Regular Monitoring**: Keep track of symptoms and flare-ups in a journal to identify potential triggers and patterns.
2. **Medication Adherence**: Follow the prescribed medication regimen, which may include anti-inflammatory drugs or biologics, to control symptoms and reduce inflammation.
3. **Healthy Diet**: Maintain a balanced diet rich in fruits, vegetables, lean protein, and whole grains to support overall health and reduce inflammation.
4. **Stress Management**: Practice stress-reducing techniques such as meditation, deep breathing exercises, or yoga, as stress can exacerbate symptoms.
5. **Hydration**: Stay well-hydrated to help the body function optimally.
6. **Regular Exercise**: Engage in regular, moderate exercise to boost immune function and overall well-being. Avoid overexertion, which can trigger flare-ups.
7. **Adequate Rest**: Ensure sufficient sleep and rest to allow the body to recover and manage inflammation.
8. **Avoid Known Triggers**: Identify and avoid specific environmental or dietary triggers that may precipitate episodes.

Consult with healthcare providers for personalized management plans and regular medical follow-ups.
Medication: Autosomal Dominant Familial Periodic Fever (also known as Familial Mediterranean Fever or FMF) is typically managed with medications to reduce inflammation and control symptoms. Common medications include:

1. **Colchicine**: This is the primary treatment and helps prevent attacks and complications.
2. **NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)**: Used to relieve pain and inflammation during attacks.
3. **Corticosteroids**: Sometimes prescribed to control severe inflammatory episodes.
4. **Biologic agents (e.g., IL-1 inhibitors)**: Anakinra, canakinumab, or rilonacept may be used for patients who do not respond to colchicine.

Always consult a healthcare professional for personalized medical advice.
Repurposable Drugs: Information on repurposable drugs for autosomal dominant familial periodic fever, also known as Familial Mediterranean Fever (FMF), may include the use of certain anti-inflammatory and immunomodulatory drugs that are typically used for other conditions but might provide therapeutic benefits for FMF as well. Colchicine, an ancient anti-inflammatory drug, is the cornerstone of FMF treatment and helps prevent attacks and complications. NSAIDs, like indomethacin, can be used to alleviate symptoms during acute attacks. Biologic agents such as IL-1 inhibitors (anakinra, canakinumab) and TNF inhibitors (etanercept) are often considered for patients who do not respond adequately to colchicine.

Given the complexity of drug repurposing and individual patient responses, it is important for healthcare professionals to tailor treatments on a case-by-case basis.
Metabolites: Autosomal dominant familial periodic fever, also known as tumor necrosis factor receptor-associated periodic syndrome (TRAPS), does not have well-defined specific metabolites associated with its diagnosis. The condition is primarily identified through genetic testing for mutations in the TNFRSF1A gene. However, inflammation markers like C-reactive protein (CRP) and serum amyloid A (SAA) can be elevated during fever episodes, reflecting the inflammatory nature of the disease.
Nutraceuticals: For autosomal dominant familial periodic fever, there is no established evidence that nutraceuticals are effective in managing this condition. Treatment typically focuses on controlling inflammation and managing symptoms through medications such as colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), or biologics like interleukin-1 inhibitors. It's important to consult with a healthcare provider for personalized medical advice.
Peptides: Autosomal Dominant Familial Periodic Fever (ADFPE) is associated with recurring episodes of fever and inflammation. Peptides, specifically Amyloidosis-associated Protease Inhibitor (AA-P1), may play a role in the inflammatory process of this condition. Nucleotide-binding oligomerization domain-containing protein 3 (NLRP3) is also involved in the disease mechanism, where mutations can lead to dysregulated inflammation. Further research is needed to fully elucidate the role of these peptides and proteins in ADFPE.